{"id":"trastuzumab-and-neratinib","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Diarrhea"},{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Vomiting"},{"rate":"20-40","effect":"Fatigue"},{"rate":"15-30","effect":"Rash"},{"rate":"5-15","effect":"Left ventricular dysfunction"},{"rate":"5-10","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets HER2-positive cancers by dual inhibition of the HER2 pathway. Trastuzumab provides antibody-mediated cellular cytotoxicity and blocks ligand-independent signaling, while neratinib provides irreversible kinase inhibition to prevent compensatory signaling and overcome resistance. The complementary mechanisms aim to achieve more complete HER2 pathway suppression than either agent alone.","oneSentence":"Trastuzumab and neratinib together block HER2 signaling through complementary mechanisms: trastuzumab is a monoclonal antibody that binds HER2 extracellularly, while neratinib is a tyrosine kinase inhibitor that irreversibly blocks HER2 and other ErbB family kinases intracellularly.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:50.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (early-stage or metastatic)"}]},"trialDetails":[{"nctId":"NCT05372614","phase":"PHASE1","title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-05","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04886531","phase":"PHASE2","title":"Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","status":"RECRUITING","sponsor":"Ruth O'Regan","startDate":"2022-07-21","conditions":"Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer","enrollment":30},{"nctId":"NCT03101748","phase":"PHASE1, PHASE2","title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-19","conditions":"Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":34},{"nctId":"NCT06109467","phase":"PHASE2","title":"Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-01-12","conditions":"GastroEsophageal Cancer, Gastric Cancer","enrollment":36},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT07333937","phase":"PHASE2","title":"Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-12-20","conditions":"Brest Cancer","enrollment":35},{"nctId":"NCT05274048","phase":"PHASE1","title":"Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2022-06-24","conditions":"Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation","enrollment":18},{"nctId":"NCT05760612","phase":"PHASE3","title":"Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-03-14","conditions":"Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab","enrollment":300},{"nctId":"NCT07152782","phase":"PHASE2","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11","conditions":"Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer","enrollment":202},{"nctId":"NCT03094052","phase":"PHASE2","title":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-10-09","conditions":"HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7","enrollment":11},{"nctId":"NCT07019272","phase":"","title":"Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-06-30","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT05615818","phase":"PHASE3","title":"Personalized Medicine for Advanced Biliary Cancer Patients","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-18","conditions":"Biliary Tract Neoplasms","enrollment":800},{"nctId":"NCT06083662","phase":"PHASE2","title":"Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2021-06-15","conditions":"Metastatic Cancer, HER2 Gene Mutation","enrollment":42},{"nctId":"NCT01953926","phase":"PHASE2","title":"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","status":"TERMINATED","sponsor":"Puma Biotechnology, Inc.","startDate":"2013-09-30","conditions":"Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","enrollment":582},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT06015113","phase":"NA","title":"Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Xi'an International Medical Center Hospital","startDate":"2023-09","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT02236000","phase":"PHASE1, PHASE2","title":"A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2014-08","conditions":"Breast Cancer","enrollment":49},{"nctId":"NCT04638725","phase":"","title":"Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2021-12-15","conditions":"HER2-positive Breast Cancer","enrollment":9000},{"nctId":"NCT01670877","phase":"PHASE2","title":"Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-12-11","conditions":"Breast Neoplasms","enrollment":56},{"nctId":"NCT03457896","phase":"PHASE2","title":"Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2018-05-18","conditions":"Metastatic Colorectal Cancer","enrollment":35},{"nctId":"NCT04856475","phase":"PHASE2","title":"Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2021-11-24","conditions":"Breast Cancer, Brain Metastases","enrollment":""},{"nctId":"NCT01008150","phase":"PHASE2","title":"Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2010-10","conditions":"Breast Cancer","enrollment":141},{"nctId":"NCT04760431","phase":"PHASE2","title":"TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-10-01","conditions":"HER2-positive Breast Cancer, Brain Metastases","enrollment":120},{"nctId":"NCT01111825","phase":"PHASE1, PHASE2","title":"Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2010-04","conditions":"Breast Cancer","enrollment":99},{"nctId":"NCT00741260","phase":"PHASE1, PHASE2","title":"Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2008-12-09","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT00915018","phase":"PHASE2","title":"Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2009-08-21","conditions":"Breast Cancer","enrollment":479},{"nctId":"NCT00300781","phase":"PHASE2","title":"Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2006-08-04","conditions":"Breast Neoplasms, Neoplasms","enrollment":136},{"nctId":"NCT00398567","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2007-04-04","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT02593708","phase":"PHASE1","title":"Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+","status":"TERMINATED","sponsor":"Michelle Melisko","startDate":"2015-11-03","conditions":"Solid Tumor","enrollment":6},{"nctId":"NCT01423123","phase":"PHASE1","title":"Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2011-05","conditions":"Breast Cancer","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":272,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trastuzumab and neratinib","genericName":"Trastuzumab and neratinib","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab and neratinib together block HER2 signaling through complementary mechanisms: trastuzumab is a monoclonal antibody that binds HER2 extracellularly, while neratinib is a tyrosine kinase inhibitor that irreversibly blocks HER2 and other ErbB family kinases intracellularly. Used for HER2-positive breast cancer (early-stage or metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}